Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

799 results about "Glucose lowering" patented technology

Reduced digestible carbohydrate food having reduced blood glucose response

Reducing the digestion of digestible carbohydrates in a digestible carbohydrate-based material, and reducing the absorption of the digestion product(s) of digestible carbohydrates (that is, simple sugars) within the small intestine. The undigested digestible carbohydrate and the unabsorbed digestion products pass through the small intestines and into the colon, where they are fermented. In effect, the food materials made by practicing the present invention cause a controlled amount of digestible carbohydrate to by-pass the small intestine, resulting in the fermentation of digestible carbohydrates in the colon. The invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to form a reduced digestible carbohydrate food having a protective food film network, which can inhibit or prevent digestion of the digestible carbohydrate. The present invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to provide a resulting reduced digestible carbohydrate food containing a viscosity-building component that contributes to the formation of a viscous intestinal chyme that can inhibit or prevent digestion of the digestible carbohydrate and can inhibit adsorption of digestion products of digestible carbohydrates in the small intestine.
Owner:TECHCOM GRP LLC

Peptide agonists of GLP-1 activity

Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and / or regulation of gastric emptying, such as diabetes and eating disorders.
Owner:LARSEN BJARNE DUE +2

Reducing ER stress in the treatment of obesity and diabetes

InactiveUS20060073213A1Reduce ER stressIncrease insulin sensitivitySalicyclic acid active ingredientsBiocidePeripheral insulin resistanceTauroursodeoxycholic acid
Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses

A composition is provided which contains policosanol and chromium and / or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol and / or lean body mass in humans and animals. The method comprises administering policosanol and chromium and / or chromium salts which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and / or chromium salts.
Owner:WYETH

Reducer of blood glucose level increase reducer of body fat accumulation and food material

A reducer of blood glucose level increase comprising palatinose as an active ingredient, wherein the reducer is ingested before or after or simultaneously with consuming a carbohydrate having an alpha-1, 6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides to reduce an increase in blood glucose level caused by ingesting the carbohydrate.
Owner:MITSUI SUGAR CO LTD

Solid beverage having assisted blood glucose lowering function, and preparation method thereof

The invention relates to a solid beverage having an assisted blood glucose lowering function, and a preparation method thereof, wherein the main function components are three or more than three materials selected from kelp or a kelp extract, potassium alginate (low molecular weight potassium alginate), common yam rhizome or a common yam rhizome extract, Chinese wolfberry or a Chinese wolfberry extract, radix puerariae or a radix puerariae extract, mulberry leaf or a mulberry leaf extract, a polygonatum odoratum extract, a bitter gourd extract, the leaf of cyclocarya paliurus and corn stigma, the auxiliary materials comprise one or more than one materials selected from inulin, resistant dextrin, bean powder, tea powder, pumpkin powder, soybean protein powder, barley leaf powder, oat fiber powder, konjac powder and citrus fiber powder, and the flavoring agent is one or a plurality of materials selected from stevioside, xylitol, fructo oligosaccharide, isomaltitol, sucralose, trehalose, matcha powder, and fruit and vegetable powder. The preparation method comprises: 1, crushing, and screening; 2, weighing; 3, carrying out mixing stirring, or carrying out stirring mixing and granulation; and 4, packaging. The solid beverage of the present invention has advantages of significant blood glucose lowering effect, good safety, and no side effect.
Owner:DALIAN YAWEITE BIOTECH

High-activity exendin-4 analogue and pharmaceutical application thereof

The invention discloses an exendin-4 analogue.Under stimulation of the analogue, islet cell tumor cells INS-1 of a rat can secrete insulin significantly more actively than that under the simulation of wild exendin-4, and hypoglycemic activity in the body of a diabetic model mouse C57B L / KsJ-db / db is significantly better than that under the simulation of wild exendin-4; the exendin-4 analogue is useful to prevent, treat or alleviate diabetics and obesity as well as other diseases benefiting from glucose reduction, gastrointestinal activity inhibition and gastric emptying.
Owner:CHINA PHARM UNIV

Etractive of fenugreek and its producing method

A feungreek extract containing the common saponin of feungreek for preventing and treating diabetes and its chronic complications is prepared through extracting with alcohol, macroreticular adsorption, washing for removing impurities, eluting, concentrating the eluting liquid, and drying.
Owner:XINJIANG TEFENG PHARMA +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products